Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3568-3576

  Parr, Christian ^a   Sanders, Andrew J ^a   Davies, Gaynor ^a   Martin, Tracey ^a   Lane, Jane ^a   Mason, Malcolm D ^b   Mansel, Robert E ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIPTASE; MATRIPTASE 2; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TUMOR GROWTH;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES;

EID: 34250777391     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2357     Document Type: Article

References (33)

1. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001;276:857-60.
2. Kitamoto Y, Veile RA, Donis-Keller H, Sadler JE. cDNA sequence and chromosomal localization of human enterokinase, the proteolytic activator of trypsinogen. Biochemistry 1995;34:4562-8.
3. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999;274:18231-6.
4. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A 1999;96:11054-61.
5. Leytus SP, Loeb KR, Hagen FS, Kurachi K, Davie EW. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 1988;27:1067-74.
6. Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692-6.
7. Wallrapp C, Hahnel S, Muller-Pillasch F, et al. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res 2000;60:602-6.
8. Yan W, Sheng N, Seto M, Morser J, Wu Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 1999;274:14926-35.
9. Lang JC, Schuller DE. Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br J Cancer 2001;84:237-43.
10. Velasco G, Cal S, Quesada V, Sanchez LM, Lopez-Otin C. Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 2002;277:7637-46.
11. Netzel-Arnett S, Hooper JD, Szabo R, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003;22:237-58.
12. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localisation of membrane-type serine protease1 and identification of protease activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000;275:26333-42.
13. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000;275:36720-5.
14. Oberst M, Anders J, Xie B, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001;158:1301-11.
15. Kang JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63:1101-5.
16. Santin AD, Cane' S, Bellone S, et al. The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 2003;98:1898-904.
17. Oberst MD, Johnson MD, Dickson RB, et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002;8:1101-7.
18. Johnson MD, Oberst MD, Lin CY, Dickson RB. Possible role of matriptase in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2003;3:331-8.
19. Suzuki M, Kobayashi H, Kanayama N, et al. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 2004;279:14899-908.
20. Galkin AV, Mullen L, Fox WD, et al. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004;61:228-35.
21. List K, Szabo R, Molinolo A, et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005;19:1934-50.
22. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004;10:202-11.
23. Jiang WG, Douglas-Jones A, Mansel RE. Level of expression of PPAR-γ and its co-activator (PPAR-GCA) in human breast cancer. Int J Cancer 2003;106:752-7.
24. Parr C, Jiang WG. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 2006;119:1176-83.
25. Jiang WG, Davies G, Fodstad O. Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-β connection. Biochem Biophys Res Commun 2005;330:253-62.
26. Parr C, Jiang WG. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 2001;19:857-63.
27. Benaud CM, Oberst M, Dickson RB, Lin CY. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 2002;19:639-49.
28. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 2005;579:1945-50.
29. Vasioukhin V. Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 2004;3:1394-7.
30. Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
31. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
32. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002;62:6812-6.
33. Hartikainen JM, Tuhkanen H, Kataja V, et al. Refinement of the 22q12-q13 breast cancer-associated region: evidence of TMPRSS6 as a candidate gene in an Eastern Finnish population. Clin Cancer Res 2006;12:1454-62.